Multi-drug resistance 1 polymorphism is associated with reduced risk of gastric cancer in the Japanese population

Journal of Gastroenterology and Hepatology (Australia)

Volumn 22, Issue 10, 2007, Pages 1678-1682

  Tahara, Tomomitsu ^a,c   Arisawa, Tomiyasu ^a   Shibata, Tomoyuki ^a   Hirata, Ichiro ^a   Nakano, Hiroshi ^b  

^a Fujita Health University   (Japan)

^b FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NONE   (Japan)

Author keywords

Gastric cancer; H. pylori; Host genetic factors; MDR1; Polymorphism

Indexed keywords

MULTIDRUG RESISTANCE PROTEIN 1;

ADULT; ADVANCED CANCER; ARTICLE; CANCER INVASION; CANCER RISK; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; JAPANESE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; STOMACH CANCER;

EID: 34548526274     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2007.04848.x     Document Type: Article

References (42)

1. Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: global burden of disease study. Lancet 1997 349 : 1269 76.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: globocan 2000. Int. J. Cancer 2001 94 : 153 6.
3. IARC. Working group on the evaluation of carcinogenic risks to humans. Lyon, Schistosomes, liver flukes and Helicobacter pylori. IARC Monogr. Eval Carcinog Risks Hum. 1994 61 : 1 241.
4. Higgins CF. ABC transporters: from microorganisms to man. Annu. Rev. Cell Biol. 1992 8 : 67 113.
5. van Veen HW, Venema K, Bolhuis H et al. Multidrug resistance mediated by a bacterial homolog of the human multidrug transporter MDR1. Proc. Natl. Acad. Sci. USA 1996 93 : 10668 72.
6. van Veen HW, Konings WN. The ABC family of multidrug transporters in microorganisms. Biochim. Biophys. Acta 1998 1365 : 31 6.
7. Dean M, Rzhetsky A, Allikmets R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res. 2001 11 : 1156 66.
8. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu. Rev. Pharmacol. Toxicol. 1999 39 : 361 98.
9. Johnstone RW, Ruefli AA, Smyth MJ. Multiple physiological functions for multidrug transporter P-glycoprotein? Trends Biochem. Sci. 2000 25 : 1 6.
10. Yamada T, Mori Y, Hayashi R et al. Suppression of intestinal polyposis in Mdr1-deficient ApcMin/+ mice. Cancer Res. 2003 63 : 895 901.
11. Cascorbi I, Gerloff T, Johne A et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin. Pharmacol. Ther. 2001 69 : 169 74.
12. Hoffmeyer S, Burk O, von Richter O et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. USA 2000 97 : 3473 8.
13. Siegsmund M, Brinkmann U, Schaffeler E et al. Association of the P-glycoprotein transporter MDR1 (C3435T) polymorphism with the susceptibility to renal epithelial tumors. J. Am. Soc. Nephrol. 2002 13 : 1847 54.
14. Schwab M, Schaeffeler E, Marx C et al. Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. Gastroenterology 2003 124 : 26 33.
15. Lauren P. The two histrogical main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol. Microbiol. Scand. 1965 64 : 31 49.
16. Drozdzik M, Bialecka M, Mysliwiec K, Honczarenko K, Stankiewicz J, Sych Z. Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinson's disease. Pharmacogenetics 2003 13 : 259 63.
17. Correa P. Helicobacter pylori and gastric carcinogenesis. Am. J. Surg. Pathol. 1995 19 (Suppl. 1 S37 43.
18. Uemura N, Okamoto S, Yamamoto S et al. Helicobacter pylori infection and the development of gastric cancer. N. Engl. J. Med. 2001 345 : 784 9.
19. Weinstein RS, Jakate SM, Dominguez JM et al. Relationship of the expression of the multidrug resistance gene product (P-glycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis. Cancer Res. 1991 51 : 2720 6.
20. Decker DA, Morris LW, Levine AJ, Pettinga JE, Grudzien JL, Farkas D. Immunohistochemical analysis of P-glycoprotein expression in breast cancer: clinical correlations. Ann. Clin. Lab. Sci. 1995 25 : 52 9.
21. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2002 2 : 48 58.
22. Materna V, Pleger J, Hoffmann U, Lage H. RNA expression of MDR1/P-glycoprotein, DNA-topoisomerase I, and MRP2 in ovarian carcinoma patients: correlation with chemotherapeutic response. Gynecol. Oncol. 2004 94 : 152 60.
23. Linn SC, Giaccone G, van Diest PJ et al. Prognostic relevance of P-glycoprotein expression in breast cancer. Ann. Oncol. 1995 6 : 679 85.
24. Baldini N, Scotlandi K, Barbanti-Brodano G et al. Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. N. Engl. J. Med. 1995 333 : 1380 5.
25. Chan HS, Thorner PS, Haddad G, Ling V. Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood. J. Clin. Oncol. 1990 8 : 689 704.
26. Willman CL. The prognostic significance of the expression and function of multidrug resistance transporter proteins in acute myeloid leukemia: studies of the Southwest Oncology Group Leukemia Research Program. Semin. Hematol. 1997 34 (4 Suppl. 5 25 33.
27. Gurel S, Yerci O, Filiz G et al. High expression of multidrug resistance-1 (MDR-1) and its relationship with multiple prognostic factors in gastric carcinomas in patients in Turkey. J. Int. Med. Res. 1999 27 : 79 84.
28. Singh B, Berry JA, Shoher A, Ramakrishnan V, Lucci A. COX-2 overexpression increases motility and invasion of breast cancer cells. Int. J. Oncol. 2005 26 : 1393 9.
29. Mobius C, Stein HJ, Spiess C et al. COX2 expression, angiogenesis, proliferation and survival in Barrett's cancer. Eur J. Surg. Oncol. 2005 31 : 755 9.
30. Wild PJ, Kunz-Schughart LA, Stoehr R et al. High-throughput tissue microarray analysis of COX2 expression in urinary bladder cancer. Int. J. Oncol. 2005 27 : 385 91.
31. Nardone G, Rocco A, Vaira D, Staibano S et al. Expression of COX-2, mPGE-synthase1, MDR-1 (P-gp), and Bcl-xL: a molecular pathway of H pylori-related gastric carcinogenesis. J. Pathol. 2004 202 : 305 12.
32. Kim RB, Leake BF, Choo EF et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin. Pharmacol. Ther. 2001 70 : 189 99.
33. Fellay J, Marzolini C, Meaden ER et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 2002 359 : 30 6.
34. Hitzl M, Drescher S, van der Kuip H et al. The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine om CD56+ natural killer cells. Pharmacogenetic 2001 11 : 293 8.
35. Nakamura T, Sakaeda T, Horinouchi M et al. Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duoden enterocytes of healthy Japanese subjects. Clin. Pharmacol. Ther. 2002 71 : 297 303.
36. Glatt HR. An overview of bioactivation of chemical carcinogens. Biochem. Soc. Trans. 2000 28 : 1 6.
37. Indulski JA, Lutz W. Metabolic genotype in relation to individual susceptibility to environmental carcinogens. Int. Arch. Occup Environ. Health 2000 73 : 71 85.
38. Cai L, Yu SZ, Zhang ZF. Glutathione S-transferases M1, T1 genotypes and the risk of gastric cancer: a case-control study. World J. Gastroenterol. 2001 7 : 506 9.
39. Sugimoto M, Furuta T, Shirai N et al. Poor metabolizer genotype status of CYP2C19 is a risk factor for developing gastric cancer in Japanese patients with Helicobacter pylori infection. Aliment Pharmacol. Ther. 2005 22 : 1033 40.
40. Ameyaw MM, Regateiro F, Li T et al. MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics 2001 11 : 217 21.
41. Sakaeda T, Nakamura T, Horinouchi M. MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm. Res. 2001 18 : 1400 4.
42. Bernal ML, Sinues B, Fanlo A, Mayayo E. Frequency distribution of C3435T mutation in exon 26 of the MDR1 gene in a Spanish population. Ther. Drug Monit. 2003 25 : 107 11.